Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in
cancer treatment is enhancing the
tumor-specific targeting of both imaging probes and
anticancer agents. Herein, we report
tumor-homing
chitosan-based nanoparticles (CNPs) that simultaneously execute
cancer diagnosis and
therapy (
cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by
tumor cells. These properties are critical in increasing their
tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with
Cy5.5, a near-infrared fluorescent (NIRF)
dye, for imaging and also loaded them with
paclitaxel (PTX-CNPs), an anticancer drug, for
cancer treatment.
Cy5.5 labeled PTX-CNPs exhibited significantly increased
tumor-homing ability with low nonspecific uptake by other tissues in SCC7
tumor-bearing mice. Theragnostic nanoparticles,
Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage
cancer and drug delivery.